Alnylam Grants CEO New Performance-Based Equity Award
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Alnylam Pharma ( (ALNY) ).
Effective March 2, 2026, Alnylam’s board granted CEO Yvonne Greenstreet a special, fully performance-based equity award designed to retain and incentivize her as the company pursues its new “Alnylam 2030” five-year goals, after she led nearly 100% shareholder return and achievement of the “P5x25” profitability targets by 2025. The award, with a face value of about $18 million at grant, can vest between 50% and 200% of 55,373 performance share units only if Alnylam’s stock sustains substantial appreciation to at least $500 over a 30-day average before December 31, 2029, with vesting and forfeiture terms tied to continued service, termination conditions and change-in-control pricing to closely align her incentives with long-term shareholder value.
The most recent analyst rating on (ALNY) stock is a Hold with a $360.00 price target. To see the full list of analyst forecasts on Alnylam Pharma stock, see the ALNY Stock Forecast page.
Spark’s Take on ALNY Stock
According to Spark, TipRanks’ AI Analyst, ALNY is a Neutral.
The score is driven by a meaningful 2025 financial and cash-flow inflection and a bullish earnings-call outlook with strong 2026 growth guidance. These positives are tempered by balance-sheet leverage and historical volatility, while the stock’s technical trend is notably weak and valuation is highly demanding (very high P/E), increasing downside risk if execution or growth expectations slip.
To see Spark’s full report on ALNY stock, click here.
More about Alnylam Pharma
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing RNA interference (RNAi) therapeutics. Under the leadership of CEO Yvonne Greenstreet, it has launched AMVUTTRA for multiple indications, including a landmark 2025 approval for TTR cardiomyopathy, and built a clinical pipeline with over 25 active programs, including several Phase 3 trials.
Average Trading Volume: 1,573,464
Technical Sentiment Signal: Hold
Current Market Cap: $42.26B
For an in-depth examination of ALNY stock, go to TipRanks’ Overview page.
